IMV Inc., a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, yesterday announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors (“Board”) of the Company, effective immediately.
Dr. Tilley, Managing Partner at CTI Life Sciences Fund (“CTI LSF”), was originally appointed to the IMV Board in 2016 as a representative from CTI LSF following their initial investment in IMV. Dr. Tilley’s resignation arose due to policy changes surrounding board positions at CTI LSF and she will remain IMV’s point of contact at CTI LSF.
“Dr. Tilley has been a valuable member of the board and we have appreciated her experience in the industry and thoughtful guidance,” said Michael Bailey, Chairman of the Board. “On behalf of the Board of Directors, I want to thank Shermaine for her service and commitment to IMV during the last seven years. We wish her all the best.” Following Dr. Tilley’s resignation, the Company has appointed Brittany Davison, Chief Accounting Officer at IMV to its Board in an interim capacity while the search for a Canadian replacement is ongoing.
Also read the articles on:
Barry Coflan joins Xendee’s Board of Directors
Oxford Bank Corporation appoints two executives to its Board of Directors